Innate Pharma S.A. (IPHA) Financials

IPHA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 71.8 million 96.7 million
Dec. 31, 2025 73.6 million 99.1 million
June 30, 2025 109.5 million 103.5 million
March 31, 2025 120.1 million 110.6 million

IPHA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -26.9 million ?
Dec. 31, 2025 -27.6 million ?
June 30, 2025 -40.2 million 1.8 million
March 31, 2025 -10.9 million 2.4 million

IPHA Net Income

No data available :(

IPHA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 39.3 million - -
Dec. 31, 2025 40.3 million 16.2 million 450802
June 30, 2025 70.8 million 21.1 million 724876
March 31, 2025 87.4 million - -

IPHA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 104.8 million
Dec. 31, 2025 107.3 million
June 30, 2025 102.5 million
March 31, 2025 87.7 million

IPHA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 97466 26.3 million 1.6 million -
Dec. 31, 2025 99847 26.9 million 1.4 million -183138
June 30, 2025 74665 24.2 million 11.5 million 183871
March 31, 2025 116835 24.8 million 2.7 million 177417

IPHA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 -2.4 million -
Dec. 31, 2025 -2.4 million -
June 30, 2025 5.7 million 24.2 million
March 31, 2025 298580 -31.5 million

IPHA

Price: $1.76

52 week price:
1.17
2.63

Earnings Per Share: -0.64 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: France

Volume: 6529

Market Capitalization: 168.1 million

Links: